Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system).
In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause the nerves themselves to deteriorate or become permanently damaged.
Signs and symptoms of MS vary widely and depend on the amount of nerve damage and which nerves are affected. Some people with severe MS may lose the ability to walk independently or at all, while others may experience long periods of remission without any new symptoms.
There's no cure for multiple sclerosis. However, treatments can help speed recovery from attacks, modify the course of the disease and manage symptoms.
Find out why Mayo Clinic is the best place for your care.
Aug. 04, 2017
- AskMayoExpert. What is multiple sclerosis? Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
- Daroff RB, et al. Bradley's Neurology in Clinical Practice. 6th ed. Philadelphia, Pa.: Elsevier Saunders; 2012. https://www.clinicalkey.com. Accessed Dec. 16, 2014.
- Ferri FF. Ferri's Clinical Advisor 2014: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2015. https://www.clinicalkey.com. Accessed April 4, 2014.
- Olek MJ. Epidemiology and clinical features of multiple sclerosis in adults. http://www.uptodate.com/home. Accessed April 4, 2014.
- Wingerchuk DM (expert opinion). Mayo Clinic, Phoenix/Scottsdale, Ariz. May 13, 2014.
- Kantarci O. Treatment of primary progressive multiple sclerosis. Seminars in Neurology. 2013;33:74.
- Keegan BM. Therapeutic decision making in a new drug era in multiple sclerosis. Seminars in Neurology. 2013;33:5.
- Goldman L, et al. Goldman's Cecil Medicine. 24th ed. Philadelphia, Pa.: Saunders Elsevier; 2012. http://www.clinicalkey.com. Accessed April 4, 2014.
- Lotze TE. Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis. http://www.uptodate.com/home. Accessed April 5, 2014.
- Kantarci OH, et al. Novel immunomodulatory approaches for the management of multiple sclerosis. Clinical Pharmacology & Therapeutics. 2014;95:32.
- Olek MJ. Treatment of relapsing-remitting multiple sclerosis in adults. http://www.uptodate.com/home. Accessed Dec. 16, 2014.
- Olek MJ. Treatment of acute exacerbations of multiple sclerosis in adults. http://www.uptodate.com/home. Accessed April 4, 2014.
- Wingerchuk DM. Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies. Mayo Clinic Proceedings. 2014;89:225.
- Pizzorno JE, et al. Textbook of Natural Medicine. 4th ed. St. Louis, Mo.: Churchill Livingstone Elsevier; 2013. https://www.clinicalkey.com. Accessed April 4, 2014.
- Olek MJ. Diagnosis of multiple sclerosis in adults. http://www.uptodate.com/home. Accessed Jan. 2, 2015.
- Polman, C, et al. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Annals of Neurology. 2011;69:292. http://onlinelibrary.wiley.com/doi/10.1002/ana.22366/pdf.
- Patient information: Multiple sclerosis. http://www.uptodate.com/home. Accessed Jan. 2, 2015.
- Olek MJ. Symptom management of multiple sclerosis in adults. http://www.uptodate.com/home. Accessed Jan. 2, 2015.
- Yadav Y, et al. Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis. Neurology. 2014;82:1083.
- Riggin EA. Decision Support System. Mayo Clinic, Rochester, Minn. Jan. 20, 2015.
- National MS Society. Network of Pediatric MS Centers. Accessed Feb. 10, 2015. http://www.nationalmssociety.org/What-is-MS/Who-Gets-MS/Pediatric-MS/Care-for-Pediatric-MS-%28Centers-of-Excellence%29.
- Rodriguez M. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology. 1993;43:1100.
- Deb C. CD8+ T cells cause disability and axon loss in a mouse model of multiple sclerosis. PLOS One. Aug. 30, 2010.
- FDA approves new drug to treat multiple sclerosis. FDA. Accessed March 29, 2017.